Search research articles
Contact Us
Filters
Showing results (21-30 of 26) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 26 results.
The Lancet. Oncology
|
November 18, 2017
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Miguel Martin, Frankie A Holmes, Bent Ejlertsen, et al.
Nature
|
April 8, 2024
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
Jean E Abraham, Karen Pinilla, Alimu Dayimu, et al.
British Journal of Cancer
|
July 7, 2023
Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial
Nalinie Joharatnam-Hogan, Duaa Hatem, Fay H Cafferty, et al.
Nature Communications
|
May 13, 2025
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial
Jean E Abraham, Lenka Oplustil O'Connor, Louise Grybowicz, et al.
Cancers
|
August 26, 2022
An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves
Oskar Wysocki, Cong Zhou, Jacobo Rogado, et al.
JCO Clinical Cancer Informatics
|
May 24, 2022
Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital
Rebecca J Lee, Oskar Wysocki, Cong Zhou, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 26) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 26 results.
The Lancet. Oncology
|
November 18, 2017
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
Miguel Martin, Frankie A Holmes, Bent Ejlertsen, et al.
Nature
|
April 8, 2024
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
Jean E Abraham, Karen Pinilla, Alimu Dayimu, et al.
British Journal of Cancer
|
July 7, 2023
Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial
Nalinie Joharatnam-Hogan, Duaa Hatem, Fay H Cafferty, et al.
Nature Communications
|
May 13, 2025
Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial
Jean E Abraham, Lenka Oplustil O'Connor, Louise Grybowicz, et al.
Cancers
|
August 26, 2022
An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves
Oskar Wysocki, Cong Zhou, Jacobo Rogado, et al.
JCO Clinical Cancer Informatics
|
May 24, 2022
Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital
Rebecca J Lee, Oskar Wysocki, Cong Zhou, et al.
Page
of 3